We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
ARTICLE · 25 NOVEMBER 2013
No Avoiding BPCIA For Biosimilars: No Patent Declaratory Judgment Action Before Biosimilars Application Is Filed

Sheppard
Contributor

Sheppard
Businesses turn to Sheppard to deliver sophisticated counsel to help clients move ahead. With more...
View firm profileThe United States District Court for the Northern District of California ruled November 12, 2013, that a party seeking to obtain approval of a biosimilar could not avoid the process set forth in the Biologics Price Competition and Innovation Act of 2009 ("BPCIA") by obtaining a declaratory judgment of patent invalidity before even submitting a biosimilars application.
United StatesIntellectual Property







